ES2185321T3 - Combinacion de un agonista inverso de gaba-a alfa 5 y un agosnista de la nicotina. - Google Patents

Combinacion de un agonista inverso de gaba-a alfa 5 y un agosnista de la nicotina.

Info

Publication number
ES2185321T3
ES2185321T3 ES99909110T ES99909110T ES2185321T3 ES 2185321 T3 ES2185321 T3 ES 2185321T3 ES 99909110 T ES99909110 T ES 99909110T ES 99909110 T ES99909110 T ES 99909110T ES 2185321 T3 ES2185321 T3 ES 2185321T3
Authority
ES
Spain
Prior art keywords
combination
agonist
agosnist
invested
gaba
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99909110T
Other languages
English (en)
Inventor
Gerard Raphael Dawson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Application granted granted Critical
Publication of ES2185321T3 publication Critical patent/ES2185321T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una combinación de un agonista nicotínico y 3 - (5 - metilisoxazol - 3 - il) - 6 - (1 - metil 1, 2, 3 - triazol - 4 - il)metiloxi - 1, 2, 4 - triazolo[3, 4 - a]ftalazina adecuada para administración separada, secuencial o simultánea.
ES99909110T 1998-03-16 1999-03-16 Combinacion de un agonista inverso de gaba-a alfa 5 y un agosnista de la nicotina. Expired - Lifetime ES2185321T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9805559.3A GB9805559D0 (en) 1998-03-16 1998-03-16 A combination of therapeutic agents

Publications (1)

Publication Number Publication Date
ES2185321T3 true ES2185321T3 (es) 2003-04-16

Family

ID=10828630

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99909110T Expired - Lifetime ES2185321T3 (es) 1998-03-16 1999-03-16 Combinacion de un agonista inverso de gaba-a alfa 5 y un agosnista de la nicotina.

Country Status (9)

Country Link
EP (1) EP1061925B1 (es)
JP (1) JP2002506822A (es)
AT (1) ATE226823T1 (es)
AU (1) AU752013B2 (es)
CA (1) CA2324237A1 (es)
DE (1) DE69903716T2 (es)
ES (1) ES2185321T3 (es)
GB (1) GB9805559D0 (es)
WO (1) WO1999047142A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9821179D0 (en) * 1998-09-30 1998-11-25 Merck Sharp & Dohme Therapeutic use
US6627624B1 (en) 1999-04-02 2003-09-30 Neurogen Corporation Aryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
US6281237B1 (en) 1999-04-02 2001-08-28 Neurogen Corporation N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives
US6380210B1 (en) 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6723332B2 (en) 2000-05-26 2004-04-20 Neurogen Corporation Oxomidazopyridine-carboxamides
AU2001273639A1 (en) 2000-06-26 2002-01-08 Neurogen Corporation Aryl fused substituted 4-oxy-pyridines
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE62662B1 (en) * 1989-01-06 1995-02-22 Elan Corp Plc Use of nicotine in the treatment of conditions susceptible to said treatment
GB9503601D0 (en) * 1995-02-23 1995-04-12 Merck Sharp & Dohme Method of treatment and method of manufacture of medicament
EP0915877A1 (en) * 1996-07-25 1999-05-19 MERCK SHARP & DOHME LTD. SUBSTITUTED TRIAZOLO PYRIDAZINE DERIVATIVES AS INVERSE AGONISTS OF THE GABA A?$g(a)5 RECEPTOR SUBTYPE

Also Published As

Publication number Publication date
CA2324237A1 (en) 1999-09-23
EP1061925A1 (en) 2000-12-27
ATE226823T1 (de) 2002-11-15
JP2002506822A (ja) 2002-03-05
DE69903716T2 (de) 2003-08-14
WO1999047142A1 (en) 1999-09-23
AU752013B2 (en) 2002-09-05
DE69903716D1 (de) 2002-12-05
EP1061925B1 (en) 2002-10-30
GB9805559D0 (en) 1998-05-13
AU2847799A (en) 1999-10-11

Similar Documents

Publication Publication Date Title
DE69616480D1 (de) Piperidinderivate als neurokininantagonisten
DK1200418T3 (da) Nematodicide trifluorbutener
NL300808I2 (nl) susoctocog alfa
ES2121193T3 (es) Derivados de bencimidazoles.
DK0584136T3 (da) Bestemmelse af peptidmotiver på MHC-molekyler
NO2005009I2 (no) Emselex-darifenacin. Iupac-navn: (S)-2-ä1-Ä2-(2,3 -dihydrobenzofuran-5-yl)etylÜ-3-pyrrolidinylü-2,2-difenylacetamid
NO20013444D0 (no) Triazolforbindelser med dopamin-D3-reseptor-affinet
TR200200205T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi
TR200003513T2 (tr) Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
FI964004A0 (fi) Serotoniiniantagonistien (5HT3) käyttö fibromyalgian hoitoon
ATE244018T1 (de) Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer
WO1999047131A3 (en) Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor
ES2184077T3 (es) Nuevas fenantridinas sustituidas en la posicion 6.
ATE241354T1 (de) Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis
ATE304530T1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
DK0951282T3 (da) Forebyggelse og behandling af skeletlidelse med EP2-receptorsubtype-selektive prostaglandin E2-agonister
ES2185321T3 (es) Combinacion de un agonista inverso de gaba-a alfa 5 y un agosnista de la nicotina.
DK0989973T3 (da) Chalconer med antiproliferativ aktivitet
DE60236212D1 (de) Neue isoform des gefässendothelzell wachstumshemmers (vegi)
TR199902094T2 (xx) 3-Heteroareil-4(3H)-kinazolinonlar�n atropizomerleri.
BR0012921A (pt) Compostos calcilìticos
DE60113968D1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
FI930265A (fi) Antikoagulantpeptider
TR200100240T2 (tr) Anksiyete bozukluklarının tedavisi
ATE373718T1 (de) 17867, eine menschliche aminopeptidase